Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • Guaranteed Paid Placement
  • SocialBoost
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • SocialBoost
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Slo-Niacin(R) Offers More Than 20 Years of Heart Health Support

NIACIN IS THE MOST EFFECTIVE AGENT AVAILABLE FOR RAISING HDL, SUPPORTING CHOLESTEROL MANAGEMENT


News provided by

Upsher-Smith Laboratories, Inc.

Mar 02, 2010, 07:30 ET

Share this article

Share toX

Share this article

Share toX

MAPLE GROVE, Minn., March 2 /PRNewswire/ -- Slo-Niacin®, a nonprescription dietary niacin supplement, features nicotinic acid - the most effective substance available for increasing high-density lipoprotein (HDL), "good cholesterol."(1) First used in the 1950s, nicotinic acid is the oldest of today's most commonly used agents used for lowering cholesterol.(2) Slo-Niacin® has been on the market for more than 20 years, selling nearly 10 million bottles to date.

"Slo-Niacin® contains niacin, which has been clinically proven to be an extremely effect agent for raising HDL and lowering LDL," states Mark Evenstad, president of Upsher-Smith Laboratories, Inc. "It has been studied for more than 20 years as a monotherapy for cholesterol management and as an adjunct to prescription cholesterol-lowering agents."

Niacin is a naturally occurring type of B vitamin that aids in the function of the digestive system, skin, nerves and heart health.(3) It's used to refer to both nicotinic acid and a closely related molecule, nicotinamide, but only nicotinic acid has been shown to have beneficial effects on cholesterol.(2)

When used under the care and monitoring of a healthcare provider, Slo-Niacin® has been clinically proven to raise HDL and lower low-density lipoprotein (LDL), or "bad cholesterol," total cholesterol, and triglycerides on its own and in combination with other cholesterol-lowering agents, such as statins.(4-7) Persons already taking cholesterol lowering drugs should contact a healthcare provider before taking niacin because of possible side effects.(8)

A healthy total cholesterol number should be less than 200. An estimated 102 million adults in the U.S. have total cholesterol levels that are considered borderline-high risk (200-230 mg/dL). Of this group, almost 36 million have total cholesterol levels that are considered high risk (>240 mg/dL).(9) The National Cholesterol Education Program recommends that all adults have their cholesterol checked once every five years.(10)

Dietary supplement niacin is sold in three forms: immediate-release, controlled-release and "flush-free." Immediate-release niacin can be inconvenient because it requires relatively small doses to be taken several times a day and the side effects, such as flushing, can be problematic. Controlled-release niacin, such as Slo-Niacin®, is less likely to cause flushing. Inositol hexaniacinate and nicotinamide, both referred to as "flush-free" niacin, prevent flushing but have not been shown to have any effect on cholesterol levels. Only nicotinic acid has been shown to have beneficial effects on cholesterol.(2)

Slo-Niacin® Tablets utilize a patented polygel® controlled-release delivery system, not available in other dietary supplement niacin products, that assures the gradual and measured release of niacin. It is designed to reduce the incidence of flushing commonly associated with immediate-release niacin use.(8)

Slo-Niacin® is economical and often costs less than an insurance co-payment. At approximately $16 per month for 100 500-mg tablets, Slo-Niacin® helps heart health without hurting your wallet.(11) Patients should talk with their healthcare provider about how Slo-Niacin® may help them.

Three dosage strengths (250 mg, 500 mg, and 750 mg) of Slo-Niacin® Tablets are available to meet the specific goals you set with your healthcare provider. But before using more than 500 mg daily, consult your healthcare provider, because niacin can cause side effects when used in high doses.(8) Proper monitoring by a healthcare provider can help manage side effects.

Slo-Niacin® Tablets are manufactured by Upsher-Smith Laboratories, Inc., a trusted manufacturer of high quality prescription and dietary supplement products, and are conveniently available at pharmacies and other retailers nationwide. For more information, contact a healthcare professional, call 1-800-654-2299 or visit www.Slo-Niacin.com for more information, coupons and a store locator.

About Upsher-Smith Laboratories, Inc.

Upsher-Smith Laboratories, Inc. is a rapidly growing pharmaceutical company that manufactures and markets both prescription and consumer products. Privately held since 1919, the company strives to recognize the unmet healthcare needs of our customers. Over the last 20 years that Upsher-Smith has been manufacturing Slo-Niacin®, more than 9.3 million bottles have been sold. Upsher-Smith prides itself in providing safe, effective, and economical therapies to the ever-challenged healthcare environment. For additional information about Upsher-Smith, visit www.upsher-smith.com.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Important Safety Information

Read the information leaflet provided with each bottle of Slo-Niacin® Tablets.

Do not use Slo-Niacin® Tablets if you have a known sensitivity or allergy to niacin.  Do not take niacin unless under your healthcare provider's supervision if you have heart disease (particularly, recurrent chest pain or recent heart attack), gallbladder disease, gout, arterial bleeding, glaucoma, diabetes, impaired liver function, stomach ulcers, or are pregnant or lactating.  Before taking more than 500 mg/day, call your healthcare provider.  If you are taking high blood pressure or cholesterol-lowering drugs, call your healthcare provider before taking niacin due to possible interactions.  Case reports of unexplained muscle-related complaints, including discomfort, weakness, or tenderness, have been documented with HMG-CoA Reductase Inhibitors in combination with niacin.  Increased uric acid, glucose, and abnormal liver function tests have been reported in persons taking 500 mg/day or more.  Discontinue use and call your healthcare provider immediately if you experience persistent flu-like symptoms (nausea, vomiting, not feeling well), loss of appetite, decreased and dark-colored urine, muscle discomfort or weakness, irregular heartbeat or vision problems.  Niacin may cause temporary flushing, itching and tingling, feelings of warmth and headache, particularly when beginning, increasing dosage or changing brands.  This safety information is not all-inclusive.  For more information, contact your healthcare provider, call 1-800-654-2299, or visit www.slo-niacin.com.

References:

(1) Mayo Clinic. http://www.mayoclinic.com/health/niacin/cl00036. April 13, 2009.

(2) Harvard Health Letter. "Niacin into the void: Failure of HDL cholesterol drug may be this B vitamin's big chance." April 2007.

(3) MedlinePlus. Niacin. http://www.nlm.nih.gov/medlineplus/ency/article/002409.htm. Accessed December 17, 2009.

(4) Lavie CJ, Mailander L, Milani. "Marked benefit with sustained-release niacin therapy in patients with 'isolated' very low levels of high-density lipoprotein cholesterol and coronary artery disease." Am J Cardiol. 1992;69:1083-1085.

(5) Squires RW, Allison TG, Gau GT, et al. "Low-Dose, Time-Release Nicotinic Acid: Effects in Selected Patients With Low Concentrations of High-Density Lipoprotein Cholesterol." Mayo Clin Proc. 67:855-860, 1992.

(6) Gray DR, Morgan T, Chretien SD, Kashyap ML. "Efficacy and Safety of Controlled-Release Niacin in Dyslipoproteinemic Veterans." Ann Intern Med. 1994;121:252-258.

(7) Knopp RF, Retzlaff BM, Fish B et al. "The SLIM study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia." Journal of Clinical Lipidology, Volume 3, Issue 3, Pages 167-178.

(8) Slo-Niacin product information. http://www.slo-niacin.com/images/pi.pdf. Upsher-Smith Laboratories, 2003.

(9) American Heart Association. http://www.americanheart.org/presenter.jhtml?identifier=4506. April 13, 2009.

(10) Centers for Disease Control and Prevention. http://www.cdc.gov/cholesterol/facts.htm. April 13, 2009.

(11) Drugstore.com website. http://www.drugstore.com. Accessed February 10, 2010.

SOURCE Upsher-Smith Laboratories, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.